Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP boosted its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 1.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 99,810 shares of the company’s stock after purchasing an additional 1,797 shares during the period. Wellington Management Group LLP owned approximately 0.17% of Phathom Pharmaceuticals worth $1,035,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in PHAT. Quantbot Technologies LP grew its stake in shares of Phathom Pharmaceuticals by 112.6% in the second quarter. Quantbot Technologies LP now owns 5,527 shares of the company’s stock valued at $46,000 after buying an additional 2,927 shares in the last quarter. Legal & General Group Plc grew its position in Phathom Pharmaceuticals by 20.1% in the second quarter. Legal & General Group Plc now owns 6,328 shares of the company’s stock valued at $54,000 after acquiring an additional 1,061 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Phathom Pharmaceuticals by 2,715.2% during the second quarter. Osaic Holdings Inc. now owns 4,251 shares of the company’s stock valued at $59,000 after purchasing an additional 4,100 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Phathom Pharmaceuticals by 371.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,429 shares of the company’s stock worth $87,000 after purchasing an additional 6,641 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of Phathom Pharmaceuticals in the second quarter valued at $87,000. 99.01% of the stock is currently owned by institutional investors and hedge funds.

Phathom Pharmaceuticals Trading Down 3.9 %

Shares of PHAT opened at $10.62 on Friday. Phathom Pharmaceuticals, Inc. has a one year low of $6.07 and a one year high of $17.02. The stock has a 50-day moving average price of $8.50 and a 200 day moving average price of $8.85. The company has a debt-to-equity ratio of 5.56, a quick ratio of 10.22 and a current ratio of 10.25. The company has a market capitalization of $621.06 million, a P/E ratio of -2.85 and a beta of 0.63.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its earnings results on Thursday, March 7th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.12. The business had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.93 million. During the same quarter last year, the company posted ($1.33) earnings per share. Sell-side analysts forecast that Phathom Pharmaceuticals, Inc. will post -4.22 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Molly Henderson sold 6,307 shares of the business’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $7.75, for a total value of $48,879.25. Following the completion of the sale, the chief financial officer now directly owns 98,698 shares of the company’s stock, valued at $764,909.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Phathom Pharmaceuticals news, insider Terrie Curran sold 16,851 shares of the stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $9.11, for a total transaction of $153,512.61. Following the sale, the insider now directly owns 410,784 shares of the company’s stock, valued at $3,742,242.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Molly Henderson sold 6,307 shares of Phathom Pharmaceuticals stock in a transaction dated Friday, January 19th. The shares were sold at an average price of $7.75, for a total transaction of $48,879.25. Following the completion of the transaction, the chief financial officer now directly owns 98,698 shares of the company’s stock, valued at $764,909.50. The disclosure for this sale can be found here. Insiders sold a total of 3,726,861 shares of company stock valued at $30,202,386 in the last ninety days. Corporate insiders own 27.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday, March 22nd.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.